-
Electronic (PDF)
-
Site License
-
Enterprisewide
Back Pain - Pipeline Review, H1 2012
Global Markets Direct, March 2012, Pages: 86
Back Pain – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Back Pain - Pipeline Review, H1 2012', provides an overview of the Back Pain therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. 'Back Pain - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Back Pain.
- A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Back Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Back Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Back Pain pipeline depth and focus of Back Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Back Pain Therapeutic Products under Development, Key Players in Back Pain Therapeutics, Back Pain Pipeline Overview, Back Pain Pipeline, Back Pain Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Back Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Back Pain
Back Pain Therapeutics under Development by Companies
Back Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Back Pain Therapeutics – Products under Development by Companies
Back Pain Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Back Pain Therapeutics Development
BioDelivery Sciences International, Inc.
Zogenix, Inc.
Cephalon, Inc.
Eisai Co., Ltd.
Pfizer Inc.
Mesoblast Ltd
Novogen Limited
Ache Laboratorios Farmaceuticos S/A
QRxPharma Limited
Troikaa Pharmaceuticals Ltd.
Back Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CEP-33237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eladur - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEMA Buprenorphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NV-07a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MoxDuo CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Cycloserine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zohydro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfasalazine + Methotrexate + Hydroxychloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfasalazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benztropine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Desipramine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ozone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naproxen + Cyclobenzaprine + Caffeine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Milnacipran - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E2000 + Diclofenac Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adult Mesenchymal Precursor Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATNC05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diclofenac + Thiocolchicoside - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Back Pain Therapeutics – Drug Profile Updates
Back Pain Therapeutics – Discontinued Products
Back Pain Therapeutics - Dormant Products
Back Pain – Product Development Milestones
Featured News & Press Releases
Sep 26, 2011: Collegium Pharmaceutical Announces Successful Type A Meeting With FDA For Tamper-Resistant, Extended Release Opioid
Aug 26, 2011: Janssen's NUCYNTA ER Receives FDA Approval For Management Of Moderate To Severe Chronic Pain
Aug 17, 2011: Endo Pharmaceuticals Terminates Collaboration With Grunenthal For Development Of Axomadol
Jun 30, 2011: Endo Announces Topline Results From Phase II Study Of Axomadol In Chronic Low Back Pain
Apr 29, 2011: Lilly Receives Health Canada Approval For Cymbalta For Chronic Low Back Pain
Apr 11, 2011: DURECT Announces ELADUR Phase II Study Results In Chronic Low Back Pain
Nov 30, 2010: Zogenix Completes Enrollment In ZX002 Phase III 12-Month Safety Study
Aug 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week 2010
Aug 19, 2010: Lilly Reports Approval Recommendation From FDA Advisory Committee For Expanding Pain Indications For Cymbalta
Mar 30, 2010: Lpath Rejects Merck KGaA's Proposal To Extend Opt-in Deadline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Back Pain, H1 2012
Products under Development for Back Pain – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
BioDelivery Sciences International, Inc., H1 2012
Zogenix, Inc., H1 2012
Cephalon, Inc., H1 2012
Eisai Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Mesoblast Ltd, H1 2012
Novogen Limited, H1 2012
Ache Laboratorios Farmaceuticos S/A, H1 2012
QRxPharma Limited, H1 2012
Troikaa Pharmaceuticals Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Back Pain Therapeutics – Drug Profile Updates
Back Pain Therapeutics – Discontinued Products
Back Pain Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Back Pain, H1 2012
Products under Development for Back Pain – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
